- Conditions
- Plasma Cell Leukemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Biospecimen Collection, High Throughput Screening, Laboratory Biomarker Analysis
- Procedure · Device · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 151
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Fragile X Syndrome
- Interventions
- Riluzole
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Vitamin D Deficiency, Vitamin D Insufficiency, Healthy Volunteers
- Interventions
- ALPCO 25(OH) Vitamin D CLIA Kit
- Device
- Lead sponsor
- American Laboratory Products Company
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Salem, New Hampshire
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Interventions
- panobinostat, everolimus, laboratory biomarker analysis, pharmacological study, liquid chromatography, mass spectrometry, enzyme-linked immunosorbent assay, immunohistochemistry staining method
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 2
- States / cities
- Buffalo, New York • Rochester, New York
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- Hsp90 inhibitor STA-9090, laboratory biomarker analysis, polymerase chain reaction, enzyme-linked immunosorbent assay, RNA analysis, spectrophotometry, reverse transcriptase-polymerase chain reaction, gene expression analysis
- Drug · Other · Genetic
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Detroit, Michigan • Piscataway, New Jersey + 1 more
- Conditions
- Head and Neck Cancer
- Interventions
- docetaxel, erlotinib hydrochloride, fluorescence in situ hybridization, polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, therapeutic conventional surgery, intensity-modulated radiation therapy, radiation therapy
- Drug · Genetic · Other + 2 more
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Lung Cancer
- Interventions
- erlotinib hydrochloride, gene expression analysis, protein expression analysis, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, needle biopsy
- Drug · Genetic · Other + 1 more
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- dovitinib lactate, gemcitabine hydrochloride, capecitabine, laboratory biomarker analysis, enzyme-linked immunosorbent assay, pharmacological study
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma
- Interventions
- DiviTum-TKa
- Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 18
- States / cities
- Derby, Connecticut • Fairfield, Connecticut • Glastonbury, Connecticut + 13 more
- Conditions
- Joint Infection, Infection of Hip Joint (Disorder), Infection of Shoulder Joint, Septic Arthritis
- Interventions
- Synovial Alpha-defensin assay, Synovial Neutrophil elastase assay, Synovial lactate assay, Synovial C-reactive Protein (CRP), Synovial Staphylococcus spp antigen panel, Synovial Candida spp antigen panel, Synovial Enterococcus faecalis assay, Synovial bacterial culture by BacT/Alert, Synovial Cell count + differential (CBC), Synovial Gram Stain, Synovial Leukocyte Esterase Test Strips, Synovial PCR for Kingella kingae, Serum Cell count + differential (CBC), Serum erythrocyte sedimentation rate (ESR), Serum C-reactive Protein (CRP), Serum D-dimer, Serum Procalcitonin, Blood Cultures, Optional blood testing per standard of care (ASO, anti-strep, ANA, anti-DS-DNA, HLA-B27, RF, Lyme and other inflammatory/ rheumatologic markers )
- Diagnostic Test
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 442 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • New York, New York • Collierville, Tennessee
- Conditions
- HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Metastatic Breast Cancer, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma
- Interventions
- Biospecimen Collection
- Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Recurrent Melanoma, Stage IIIc Melanoma, Stage IV Melanoma
- Interventions
- laboratory biomarker identification and analysis, biopsy, immunohistochemistry/tissue microarrays, TdT-mediated dUTP nick end labeling assay, mass spectrometry
- Other · Procedure · Genetic
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Carcinoma, Non-Small-Cell Lung, Breast Neoplasms
- Interventions
- TR(ACE) Assay Testing
- Device
- Lead sponsor
- Biological Dynamics
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 16
- States / cities
- Encinitas, California • Oceanside, California • Santa Monica, California + 13 more
- Conditions
- Prostate Cancer, Advanced Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Genitourinary Cancer
- Interventions
- Systemic therapy, StrataNGS
- Other · Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Leukemia
- Interventions
- dasatinib, vorinostat, cytogenetic analysis, gene expression analysis, mutation analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, laboratory biomarker analysis
- Drug · Genetic · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Duarte, California • Pasadena, California
- Conditions
- CRC (Colorectal Cancer)
- Interventions
- cfDNA 5mC/5hmC Sequencing (EpiDRIVE Discovery Phase), EpiDRIVE Assay (Targeted Sequencing / qPCR Validation)
- Diagnostic Test
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Recurrent Bladder Cancer, Transitional Cell Carcinoma of the Bladder
- Interventions
- sunitinib malate, immunohistochemistry staining method, TdT-mediated dUTP nick end labeling assay, light microscopy, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Interventions
- R-(-)-gossypol acetic acid, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Tampa, Florida • Baltimore, Maryland + 5 more
- Conditions
- Multiple Myeloma, Plasma Cell Neoplasm, Thromboembolism
- Interventions
- enzyme-linked immunosorbent assay, laboratory biomarker analysis, medical chart review
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Skin Diseases
- Interventions
- Micro-plasmapheresis
- Procedure
- Lead sponsor
- Martin Angst
- Other
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Healthy, Breast Cancer, Breast Cancer Female, Health Care Utilization, Health Knowledge, Attitudes, Practice, Health Personnel Attitude, Health Care Acceptability
- Interventions
- Schirmer Strip
- Other
- Lead sponsor
- Namida Lab
- Industry
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 205 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Fayetteville, Arkansas
- Conditions
- ESCC
- Interventions
- Small RNA sequencing of exo- and cf-miRNAs, RT-qPCR quantification of cf- and exo-miRNAs (SYNERGY assay), PCR-based validation (SYNERGY assay)
- Diagnostic Test
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Monrovia, California
- Conditions
- THALASSEMIA MAJOR
- Interventions
- Blood Draw/Semen Exam, Retrospective data/Chart Review/Relevant Clinical Results, Pituitary MRI
- Other
- Lead sponsor
- UCSF Benioff Children's Hospital Oakland
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Nephrolithiasis, Urosepsis
- Interventions
- Not listed
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Miami, Florida